ALB and cancer: In this strategy, HER2(+) cancer cells are pre-labeled by click-reactive trastuzumab, and subsequently, click-reactive, drug-loaded albumin nanocarriers (Alb) are delivered to enhance the internalization of drug carriers after the in situ bioorthogonal cross-linking of components, as shown in Fig. 1.